Fazio, R., Tinè, G., Villa, C., Nappo, F., Fassan, M., Ghirardini, C., Giommoni, E., Ceccon, C., Donato, S. D., Fornaro, L., Brunetti, O., Vita, F. D., Spallanzani, A., Bittoni, A., Bethaz, V., Strippoli, A., Latiano, T. P., Cardellino, G. G., Pietrantonio, F., Randon, G. (2026). Survival outcomes according to ramucirumab (RAM)-related hypertension (HTN) in patients (pts) with advanced HER2-negative gastric (G) or gastro-esophageal junction (GEJ) cancer: An exploratory analysis of the phase III ARMANI trial.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.4051